COMPANY:

Lucence

"Lucence will present new data on the clinical utility of combining circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) in a single liquid biopsy assay at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO), held May 30–June 3, 2025 in Chicago."

"Agilus Diagnostics...and Lucence...announced today that they have entered into a strategic collaboration to advance cancer diagnostics and personalised medicine in India. This collaboration will integrate Lucence’s cutting-edge molecular testing technologies into Agilus’ extensive laboratory network, offering enhanced cancer detection, treatment selection, and monitoring capabilities.Through this collaboration, Agilus Diagnostics will integrate Lucence’s advanced molecular testing solutions into its comprehensive oncology diagnostics portfolio. LiquidHALLMARK® is an ultra-sensitive, next-generation sequencing liquid biopsy that analyzes circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) for clinically relevant biomarkers across various cancers. LiquidHALLMARK® profiles actionable somatic mutations in 80 ctDNA genes and 37 ctRNA fusions."

"Lucence...announced that its LiquidHALLMARK® ctDNA and ctRNA liquid biopsy test will now be available to members of multiple Regence health plans across the Pacific Northwest and Intermountain regions. This expansion makes LiquidHALLMARK accessible to more patients who may benefit from its comprehensive genomic profiling capabilities."

"Lucence and the Diagnostics Development Hub (DxD Hub)...are collaborating to develop and pivot the use of Lucence’s multi-cancer early detection test (LucenceINSIGHT™) on alternative sample types. This collaboration represents a significant advancement in our efforts to make cancer screening more accessible to patients. We will also be partnering with local hospitals to identify and recruit eligible patients for this study. This collaborative effort aims to enhance the reach and impact of our research by leveraging the expertise and resources of our esteemed healthcare partners."

"Lucence presented promising new data on earlier cancer detection based on AmpliMark, its amplicon-based next generation sequencing technology at the 60th Annual ASCO Meeting in Chicago, May 31 – Jun 4, 2024."

"Lucence announced its receipt of confirmation that Medicare coverage for its LiquidHALLMARK® liquid biopsy test applies for patients with all stages of advanced solid tumors. This confirmation marks a significant milestone in promoting access to personalized oncology care on a broader scale."

"Lucence announced that interim results for LIQUIK, a prospective international multicenter liquid biopsy study for lung cancer, will be reported at the IASLC 2023 World Conference on Lung Cancer (WCLC) on September 9-12, 2023...Key objectives are prospective comparisons of Lucence’s LiquidHALLMARK® amplicon-based assay to tissue-based next generation sequencing (NGS), as well as to an FDA-approved circulating tumor DNA (ctDNA) liquid biopsy test."

"The American Medical Association (AMA) has granted a Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code for our LiquidHALLMARK™ liquid biopsy test. The CPT PLA code uniquely identifies the LiquidHALLMARK™ test for payors and providers, thus reducing administrative burdens and improving access."

"Lucence...announced...a strategic collaboration with Innovent Biologics, Inc. to improve access of Hong Kong patients with advanced bile duct cancer (cholangiocarcinoma) to the FDA-approved targeted treatment Pemazyre® (pemigatinib)...Under the agreement, Innovent will sponsor Lucence’s LiquidMARK™ Bile Duct test for Hong Kong patients with a diagnosis of bile duct cancer who fulfil criteria."

"Lucence will present promising new data on earlier cancer detection based on AmpliMark, its amplicon-based next generation sequencing technology at the 59th Annual ASCO Meeting in Chicago, June 2-6, 2023."

"Lucence unveiled LucenceINSIGHT™, its pioneering multi-cancer early detection (MCED) blood test, at their US headquarters...Lucence is launching LucenceINSIGHT™, an MCED test first internationally and with a follow-up U.S. launch in Q3 2023. This ctDNA-based liquid biopsy test screens for 10 common cancers in one blood draw."

"...Lucence has secured approval for its Singapore-invented cancer tests from Medicare, a US government-funded healthcare insurance programme primarily for people aged 65 years and older...The programme covers about 64 million people in the US and will reimburse patients for using Lucence’s blood test, LiquidHallmark, to detect lung cancer. In the US, there are about 150,000 new cases a year of advanced lung cancer in patients aged 65 and above."